<DOC>
	<DOCNO>NCT00451958</DOCNO>
	<brief_summary>Participants complete FE200486 CS21 study ( NCT00295750 ) could enter FE200486 CS21A study . The study continue non-discontinued participant receive treatment least 5 year .</brief_summary>
	<brief_title>A Long-term Extension Study Evaluating One-Month Dosing Regimen Degarelix Prostate Cancer Requiring Androgen Ablation Therapy</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Leuprolide</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<criteria>Inclusion/ Patients histologically proven prostate cancer stage endocrine treatment indicate . Signed informed consent The patient must complete FE 200486 CS21 Study .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>Degarelix</keyword>
	<keyword>prostate cancer</keyword>
</DOC>